Oriola Corp Class B · OMXHEX:ORIOLA
Oriola Corp Class B — Pareto Securities' Healthcare Conference 2025
18 slides from Oriola Corp Class B's conference presentation, Sep 16, 2025
Slide 1: Oriola – Creating value in health and wellbeing
Oriola – Creating value in health and wellbeing Pareto Securities’ Healthcare Conference Katarina Gabrielson, CEO 16 September 2025
Slide 2: A leading wholesaler of pharmaceuticals and health products in the Nordics
A leading wholesaler of pharmaceuticals and health products in the Nordics Oriola is a health and wellbeing company and part of the Offices: Espoo, Stockholm Distribution centres: Espoo, Enköping critical infrastructure in Finland and Sweden. As a leading Central warehouses: Espoo, Mölnlycke Dose di
Slide 3: Investment highlights
Investment highlights 1 Strong market 2 Potential for profit position in steadily improvement through growing markets operational efficiency and top-line growth 3 Positive long-term market outlook supported by ageing population, growing focus on wellbeing, shift towards online pharmaceuticals and di
Slide 4: Stable markets with solid growth opportunities
Stable markets with solid growth opportunities Pharmaceutical distribution market: Health products market: Significant growth opportunity Stable EUR 8.8. billion market in The consumer health markets in in e-commerce: Finland and Sweden with CAGR of 6% Finland and Sweden are valued at E-commerce con
Slide 5: Business model and business segments
Business model and business segments Building a healthier tomorrow by ensuring the safe and reliable distribution of pharmaceuticals and health products Distribution segment Wholesale segment1) Efficient and high-volume Growing offering and entering distribution of pharmaceuticals new sales channels
Slide 6: Business model and business segments
Business model and business segments Building a healthier tomorrow by ensuring the safe and reliable distribution of pharmaceuticals and health products Distribution segment Wholesale segment SHARE OF NET SALES 2024 SHARE OF NET SALES 2024 Customers 81% 19% NET SALES 2024 NET SALES 2024 EUR 1,364.7
Slide 7: Strategic ownership in Kronans Apotek
Strategic ownership in Kronans Apotek • Oriola owns 50% of Sweden’s pharmacy chain Kronan’s Apotek through joint venture. • Formed through merger with Apoteksgruppen in 2022 • Third-largest pharmacy chain in Sweden with approximately 500 pharmacies and online business • Net sales: EUR 1,151 million
Slide 8: A sustainable future starts with health
A sustainable future starts with health Sustainability performance ratings We have a positive impact on society and people’s lives through our services and products. SOCIETY ENVIRONMENT • Ensure safe and Near-term targets accurate deliveries • Reduce absolute Scope 1 and 2 GHG • Maintain the highest
Slide 9: The leading specialist in wholesale of pharmaceuticals and health products
The leading specialist in wholesale of pharmaceuticals and health products 16 SEP 2025 9
Slide 10: Financials
Financials 16 SEP 2025 10
Slide 11: Invoicing and net sales
Invoicing and net sales Invoicing and net sales EUR million 1,073 Invoicing 2,073 Invoicing 4-6 2025 952 1,861 • Invoicing and net sales growth was driven by both Distribution and +13% +11% Wholesale segments. 1-6 2025 • Invoicing and net sales growth was largely driven by the Distribution segment.
Slide 12: Sales margin
Sales margin Sales margin EUR million +5% 83.5 79.7 4-6 2025 • Sales margin improvement of 6% driven by the Distribution +6% segment, especially in services. 42.2 42.4 39.7 41.3 40.0 37.7 1-6 2025 • Sales margin improvement driven by the Distribution segment, generated both from volume growth and ne
Slide 13: Adjusted EBITDA
Adjusted EBITDA Adjusted EBITDA EUR million 15.7 15.6 0.4 4-6 2025 • Adjusting items totalled EUR -6.5 (0.5) million, including EUR -3.2 million ERP investment related implementation cost, EUR -2.8 8.1 million loss from the sale of dose dispensing business in Sweden 8.0 and EUR -0.5 million other co
Slide 14: Free cash flow
Free cash flow Free cash flow EUR million 1-6 2025 1-6 1-6 Abs. • EBITDA below last year due to higher adjusting EUR million 2025 2024 change items. EBITDA 7.5 15.3 -7.8 • Increase in trade payables has impacted working capital positively. Adjustments 3.3 0.0 3.3 • Taxes at last year’s level, invest
Slide 15: Solid financial position
Solid financial position Gearing and equity ratio, % Net interest-bearing debt, EUR million Q2 2025 35 30 • The impairment and 23 19 write-down in Dose 25 21 19 20 19 17 17 18 Sweden, adjusting 15 14 9 15 13 10 items (mainly ERP) and 9 5 0 the negative result from 5 Kronans Apotek had a -2 -10 -7 ne
Slide 16: Outlook for 2025
Outlook for 2025 In 2025, the pharmaceutical distribution market is expected to continue to grow. Value growth is expected to be driven by high-value pharmaceuticals and products requiring advanced logistics. The uncertainty in the geopolitical environment remains, and the availability issues of cer
Slide 17: Investment highlights
Investment highlights 1 Strong market 2 Potential for profit position in steadily improvement through growing markets operational efficiency and top-line growth 3 Positive long-term market outlook supported by ageing population, growing focus on wellbeing, shift towards online pharmaceuticals and di
Slide 18: Creating value in health and wellbeing
Creating value in health and wellbeing Contact our IR team for further information: investor.relations@oriola.com
Oriola — Pareto Securities' Healthcare Conference 2025 on 6ix